APA (7th ed.) Citation

Siyuan Zeng, Siyuan Zeng, Daju Liu, Yongai Yu, Lei Zou, Xianyu Jin, . . . Lifeng Liu. (2023). Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Siyuan Zeng, Siyuan Zeng, Daju Liu, Yongai Yu, Lei Zou, Xianyu Jin, Bing Liu, Lifeng Liu, and Lifeng Liu. Efficacy and Safety of PD-1/PD-L1 Inhibitors in the Treatment of Recurrent and Refractory Ovarian Cancer: A Systematic Review and a Meta-analysis. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Siyuan Zeng, et al. Efficacy and Safety of PD-1/PD-L1 Inhibitors in the Treatment of Recurrent and Refractory Ovarian Cancer: A Systematic Review and a Meta-analysis. Frontiers Media S.A., 2023.